Carnitine Concentration [ Time Frame: Day 1 ]
Carnitine, which plays a role to reduce oxidative stress, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Carnitine Concentration [ Time Frame: Day 2 ]
Carnitine, which plays a role to reduce oxidative stress, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Carnitine Concentration [ Time Frame: Day 35 ]
Carnitine, which plays a role to reduce oxidative stress, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Carnitine Concentration [ Time Frame: Day 36 ]
Carnitine, which plays a role to reduce oxidative stress, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Carnitine Concentration [ Time Frame: Day 70 ]
Carnitine, which plays a role to reduce oxidative stress, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Carnitine Concentration [ Time Frame: Day 71 ]
Carnitine, which plays a role to reduce oxidative stress, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Carnitine Concentration [ Time Frame: Day 105 ]
Carnitine, which plays a role to reduce oxidative stress, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Carnitine Concentration [ Time Frame: Day 106 ]
Carnitine, which plays a role to reduce oxidative stress, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Carnitine Concentration [ Time Frame: Day 140 ]
Carnitine, which plays a role to reduce oxidative stress, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Carnitine Concentration [ Time Frame: Day 141 ]
Carnitine, which plays a role to reduce oxidative stress, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Choline Concentration [ Time Frame: Day 1 ]
Choline, a molecule involved in methyl transfer and lipid formation and support of healthy blood vessels, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Choline Concentration [ Time Frame: Day 2 ]
Choline, a molecule involved in methyl transfer and lipid formation and support of healthy blood vessels, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Choline Concentration [ Time Frame: Day 35 ]
Choline, a molecule involved in methyl transfer and lipid formation and support of healthy blood vessels, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Choline Concentration [ Time Frame: Day 36 ]
Choline, a molecule involved in methyl transfer and lipid formation and support of healthy blood vessels, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Choline Concentration [ Time Frame: Day 70 ]
Choline, a molecule involved in methyl transfer and lipid formation and support of healthy blood vessels, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Choline Concentration [ Time Frame: Day 71 ]
Choline, a molecule involved in methyl transfer and lipid formation and support of healthy blood vessels, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Choline Concentration [ Time Frame: Day 105 ]
Choline, a molecule involved in methyl transfer and lipid formation and support of healthy blood vessels, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Choline Concentration [ Time Frame: Day 106 ]
Choline, a molecule involved in methyl transfer and lipid formation and support of healthy blood vessels, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Choline Concentration [ Time Frame: Day 140 ]
Choline, a molecule involved in methyl transfer and lipid formation and support of healthy blood vessels, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Choline Concentration [ Time Frame: Day 141 ]
Choline, a molecule involved in methyl transfer and lipid formation and support of healthy blood vessels, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Betaine Concentration [ Time Frame: Day 1 ]
Betaine, which helps make carnitine and supports heart health, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Betaine Concentration [ Time Frame: Day 2 ]
Betaine, which helps make carnitine and supports heart health, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Betaine Concentration [ Time Frame: Day 35 ]
Betaine, which helps make carnitine and supports heart health, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Betaine Concentration [ Time Frame: Day 36 ]
Betaine, which helps make carnitine and supports heart health, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Betaine Concentration [ Time Frame: Day 70 ]
Betaine, which helps make carnitine and supports heart health, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Betaine Concentration [ Time Frame: Day 71 ]
Betaine, which helps make carnitine and supports heart health, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Betaine Concentration [ Time Frame: Day 105 ]
Betaine, which helps make carnitine and supports heart health, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Betaine Concentration [ Time Frame: Day 106 ]
Betaine, which helps make carnitine and supports heart health, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Betaine Concentration [ Time Frame: Day 140 ]
Betaine, which helps make carnitine and supports heart health, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Betaine Concentration [ Time Frame: Day 141 ]
Betaine, which help make carnitine and supports heart health, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMA (trimethylamine) Concentration [ Time Frame: Day 1 ]
TMA (trimethylamine), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMA (trimethylamine) Concentration [ Time Frame: Day 2 ]
TMA (trimethylamine), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMA (trimethylamine) Concentration [ Time Frame: Day 35 ]
TMA (trimethylamine), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMA (trimethylamine) Concentration [ Time Frame: Day 36 ]
TMA (trimethylamine), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMA (trimethylamine) Concentration [ Time Frame: Day 70 ]
TMA (trimethylamine), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMA (trimethylamine) Concentration [ Time Frame: Day 71 ]
TMA (trimethylamine), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMA (trimethylamine) Concentration [ Time Frame: Day 105 ]
TMA (trimethylamine), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMA (trimethylamine) Concentration [ Time Frame: Day 106 ]
TMA (trimethylamine), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMA (trimethylamine) Concentration [ Time Frame: Day 140 ]
TMA (trimethylamine), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMA (trimethylamine) Concentration [ Time Frame: Day 141 ]
TMA (trimethylamine), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMAO (trimethylamine N-oxide) Concentration [ Time Frame: Day 1 ]
TMAO (trimethylamine N-oxide), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMAO (trimethylamine N-oxide) Concentration [ Time Frame: Day 2 ]
TMAO (trimethylamine N-oxide), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMAO (trimethylamine N-oxide) Concentration [ Time Frame: Day 35 ]
TMAO (trimethylamine N-oxide), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMAO (trimethylamine N-oxide) Concentration [ Time Frame: Day 36 ]
TMAO (trimethylamine N-oxide), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMAO (trimethylamine N-oxide) Concentration [ Time Frame: Day 70 ]
TMAO (trimethylamine N-oxide), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMAO (trimethylamine N-oxide) Concentration [ Time Frame: Day 71 ]
TMAO (trimethylamine N-oxide), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMAO (trimethylamine N-oxide) Concentration [ Time Frame: Day 105 ]
TMAO (trimethylamine N-oxide), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMAO (trimethylamine N-oxide) Concentration [ Time Frame: Day 106 ]
TMAO (trimethylamine N-oxide), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMAO (trimethylamine N-oxide) Concentration [ Time Frame: Day 140 ]
TMAO (trimethylamine N-oxide), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
TMAO (trimethylamine N-oxide) Concentration [ Time Frame: Day 141 ]
TMAO (trimethylamine N-oxide), a metabolite of gastrointestinal bacteria, will be analyzed in blood in units of micromol/L to assess the effect of the intervention on cardiovascular health.
Total Cholesterol Concentration [ Time Frame: Day 1 ]
Total cholesterol will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Total Cholesterol Concentration [ Time Frame: Day 2 ]
Total cholesterol will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Total Cholesterol Concentration [ Time Frame: Day 35 ]
Total cholesterol will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Total Cholesterol Concentration [ Time Frame: Day 36 ]
Total cholesterol will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Total Cholesterol Concentration [ Time Frame: Day 70 ]
Total cholesterol will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Total Cholesterol Concentration [ Time Frame: Day 71 ]
Total cholesterol will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Total Cholesterol Concentration [ Time Frame: Day 105 ]
Total cholesterol will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Total Cholesterol Concentration [ Time Frame: Day 106 ]
Total cholesterol will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Total Cholesterol Concentration [ Time Frame: Day 140 ]
Total cholesterol will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Total Cholesterol Concentration [ Time Frame: Day 141 ]
Total cholesterol will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
LDL Cholesterol Concentration [ Time Frame: Day 1 ]
LDL cholesterol, including its subfractions LDL1, LDL2, LDL3, and LDL4, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
LDL Cholesterol Concentration [ Time Frame: Day 2 ]
LDL cholesterol, including its subfractions LDL1, LDL2, LDL3, and LDL4, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
LDL Cholesterol Concentration [ Time Frame: Day 35 ]
LDL cholesterol, including its subfractions LDL1, LDL2, LDL3, and LDL4, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
LDL Cholesterol Concentration [ Time Frame: Day 36 ]
LDL cholesterol, including its subfractions LDL1, LDL2, LDL3, and LDL4, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
LDL Cholesterol Concentration [ Time Frame: Day 70 ]
LDL cholesterol, including its subfractions LDL1, LDL2, LDL3, and LDL4, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
LDL Cholesterol Concentration [ Time Frame: Day 71 ]
LDL cholesterol, including its subfractions LDL1, LDL2, LDL3, and LDL4, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
LDL Cholesterol Concentration [ Time Frame: Day 105 ]
LDL cholesterol, including its subfractions LDL1, LDL2, LDL3, and LDL4, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
LDL Cholesterol Concentration [ Time Frame: Day 106 ]
LDL cholesterol, including its subfractions LDL1, LDL2, LDL3, and LDL4, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
LDL Cholesterol Concentration [ Time Frame: Day 140 ]
LDL cholesterol, including its subfractions LDL1, LDL2, LDL3, and LDL4, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
LDL Cholesterol Concentration [ Time Frame: Day 141 ]
LDL cholesterol, including its subfractions LDL1, LDL2, LDL3, and LDL4, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
HDL Cholesterol Concentration [ Time Frame: Day 1 ]
HDL cholesterol, including its subfractions HDL2 and HDL3, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
HDL Cholesterol Concentration [ Time Frame: Day 2 ]
HDL cholesterol, including its subfractions HDL2 and HDL3, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
HDL Cholesterol Concentration [ Time Frame: Day 35 ]
HDL cholesterol, including its subfractions HDL2 and HDL3, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
HDL Cholesterol Concentration [ Time Frame: Day 36 ]
HDL cholesterol, including its subfractions HDL2 and HDL3, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
HDL Cholesterol Concentration [ Time Frame: Day 70 ]
HDL cholesterol, including its subfractions HDL2 and HDL3, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
HDL Cholesterol Concentration [ Time Frame: Day 71 ]
HDL cholesterol, including its subfractions HDL2 and HDL3, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
HDL Cholesterol Concentration [ Time Frame: Day 105 ]
HDL cholesterol, including its subfractions HDL2 and HDL3, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
HDL Cholesterol Concentration [ Time Frame: Day 106 ]
HDL cholesterol, including its subfractions HDL2 and HDL3, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
HDL Cholesterol Concentration [ Time Frame: Day 140 ]
HDL cholesterol, including its subfractions HDL2 and HDL3, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
HDL Cholesterol Concentration [ Time Frame: Day 141 ]
HDL cholesterol, including its subfractions HDL2 and HDL3, will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Triglyceride Concentration [ Time Frame: Day 1 ]
Triglycerides will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Triglyceride Concentration [ Time Frame: Day 2 ]
Triglycerides will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Triglyceride Concentration [ Time Frame: Day 35 ]
Triglycerides will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Triglyceride Concentration [ Time Frame: Day 36 ]
Triglycerides will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Triglyceride Concentration [ Time Frame: Day 70 ]
Triglycerides will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Triglyceride Concentration [ Time Frame: Day 71 ]
Triglycerides will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Triglyceride Concentration [ Time Frame: Day 105 ]
Triglycerides will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Triglyceride Concentration [ Time Frame: Day 106 ]
Triglycerides will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Triglyceride Concentration [ Time Frame: Day 140 ]
Triglycerides will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Triglyceride Concentration [ Time Frame: Day 141 ]
Triglycerides will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Apolipoprotein Concentration [ Time Frame: Day 1 ]
Apolipoproteins AI, AII, and B will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Apolipoprotein Concentration [ Time Frame: Day 2 ]
Apolipoproteins AI, AII, and B will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Apolipoprotein Concentration [ Time Frame: Day 35 ]
Apolipoproteins AI, AII, and B will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Apolipoprotein Concentration [ Time Frame: Day 36 ]
Apolipoproteins AI, AII, and B will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Apolipoprotein Concentration [ Time Frame: Day 70 ]
Apolipoproteins AI, AII, and B will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Apolipoprotein Concentration [ Time Frame: Day 71 ]
Apolipoproteins AI, AII, and B will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Apolipoprotein Concentration [ Time Frame: Day 105 ]
Apolipoproteins AI, AII, and B will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Apolipoprotein Concentration [ Time Frame: Day 106 ]
Apolipoproteins AI, AII, and B will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Apolipoprotein Concentration [ Time Frame: Day 140 ]
Apolipoproteins AI, AII, and B will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Apolipoprotein Concentration [ Time Frame: Day 141 ]
Apolipoproteins AI, AII, and B will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Lipoprotein(a) (Lp(a)) Concentration [ Time Frame: Day 1 ]
Lipoprotein(a) will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Lipoprotein(a) (Lp(a)) Concentration [ Time Frame: Day 2 ]
Lipoprotein(a) will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Lipoprotein(a) (Lp(a)) Concentration [ Time Frame: Day 35 ]
Lipoprotein(a) will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Lipoprotein(a) (Lp(a)) Concentration [ Time Frame: Day 36 ]
Lipoprotein(a) will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Lipoprotein(a) (Lp(a)) Concentration [ Time Frame: Day 70 ]
Lipoprotein(a) will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Lipoprotein(a) (Lp(a)) Concentration [ Time Frame: Day 71 ]
Lipoprotein(a) will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Lipoprotein(a) (Lp(a)) Concentration [ Time Frame: Day 105 ]
Lipoprotein(a) will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Lipoprotein(a) (Lp(a)) Concentration [ Time Frame: Day 106 ]
Lipoprotein(a) will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Lipoprotein(a) (Lp(a)) Concentration [ Time Frame: Day 140 ]
Lipoprotein(a) will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Lipoprotein(a) (Lp(a)) Concentration [ Time Frame: Day 141 ]
Lipoprotein(a) will be analyzed in blood in units of mg/dl to assess the effect of the intervention on cardiovascular health.
Low Density Lipoprotein particle size [ Time Frame: Day 1 ]
Low Density Lipoprotein particle size will be analyzed in blood in units of nm to assess the effect of the intervention on cardiovascular health.
Low Density Lipoprotein particle size [ Time Frame: Day 2 ]
Low Density Lipoprotein particle size will be analyzed in blood in units of nm to assess the effect of the intervention on cardiovascular health.
Low Density Lipoprotein particle size [ Time Frame: Day 35 ]
Low Density Lipoprotein particle size will be analyzed in blood in units of nm to assess the effect of the intervention on cardiovascular health.
Low Density Lipoprotein particle size [ Time Frame: Day 36 ]
Low Density Lipoprotein particle size will be analyzed in blood in units of nm to assess the effect of the intervention on cardiovascular health.
Low Density Lipoprotein particle size [ Time Frame: Day 70 ]
Low Density Lipoprotein particle size will be analyzed in blood in units of nm to assess the effect of the intervention on cardiovascular health.
Low Density Lipoprotein particle size [ Time Frame: Day 71 ]
Low Density Lipoprotein particle size will be analyzed in blood in units of nm to assess the effect of the intervention on cardiovascular health.
Low Density Lipoprotein particle size [ Time Frame: Day 105 ]
Low Density Lipoprotein particle size will be analyzed in blood in units of nm to assess the effect of the intervention on cardiovascular health.
Low Density Lipoprotein particle size [ Time Frame: Day 106 ]
Low Density Lipoprotein particle size will be analyzed in blood in units of nm to assess the effect of the intervention on cardiovascular health.
Low Density Lipoprotein particle size [ Time Frame: Day 140 ]
Low Density Lipoprotein particle size will be analyzed in blood in units of nm to assess the effect of the intervention on cardiovascular health.
Low Density Lipoprotein particle size [ Time Frame: Day 141 ]
Low Density Lipoprotein particle size will be analyzed in blood in units of nm to assess the effect of the intervention on cardiovascular health.
Blood Pressure [ Time Frame: Day 1 ]
Blood pressure (systolic and diastolic) will be measured as mm Hg, as a reflection of cardiovascular health.
Blood Pressure [ Time Frame: Day 2 ]
Blood pressure (systolic and diastolic) will be measured as mm Hg, as a reflection of cardiovascular health.
Blood Pressure [ Time Frame: Day 35 ]
Blood pressure (systolic and diastolic) will be measured as mm Hg, as a reflection of cardiovascular health.
Blood Pressure [ Time Frame: Day 36 ]
Blood pressure (systolic and diastolic) will be measured as mm Hg, as a reflection of cardiovascular health.
Blood Pressure [ Time Frame: Day 70 ]
Blood pressure (systolic and diastolic) will be measured as mm Hg, as a reflection of cardiovascular health.
Blood Pressure [ Time Frame: Day 71 ]
Blood pressure (systolic and diastolic) will be measured as mm Hg, as a reflection of cardiovascular health.
Blood Pressure [ Time Frame: Day 105 ]
Blood pressure (systolic and diastolic) will be measured as mm Hg, as a reflection of cardiovascular health.
Blood Pressure [ Time Frame: Day 106 ]
Blood pressure (systolic and diastolic) will be measured as mm Hg, as a reflection of cardiovascular health.
Blood Pressure [ Time Frame: Day 140 ]
Blood pressure (systolic and diastolic) will be measured as mm Hg, as a reflection of cardiovascular health.
Blood Pressure [ Time Frame: Day 141 ]
Blood pressure (systolic and diastolic) will be measured as mm Hg, as a reflection of cardiovascular health.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
